75 research outputs found
Channel gating of the glycine receptor changes accessibility to residues implicated in receptor potentiation by alcohols and anesthetics.
Abstract The glycine receptor is a target for both alcohols and anesthetics, and certain amino acids in the α1 subunit transmembrane segments (TM) are critical for drug effects. Introducing larger amino acids at these positions increases the potency of glycine, suggesting that introducing larger residues, or drug molecules, into the drug-binding cavity facilitates channel opening. A possible mechanism for these actions is that the volume of the cavity expands and contracts during channel opening and closing. To investigate this hypothesis, mutations for amino acids in TM1 (I229C) and TM2 (G256C, T259C, V260C, M263C, T264C, S267C, S270C) and TM3 (A288C) were individually expressed in Xenopus laevis oocytes. The ability of sulfhydryl-specific alkyl methanethiosulfonate (MTS) compounds of different lengths to covalently react with introduced cysteines in both the closed and open states of the receptor was determined. S267C was accessible to short chain (C3–C8) MTS in both open and closed states, but was only accessible to longer chain (C10–C16) MTS compounds in the open state. Reaction with S267C was faster in the open state. I229C and A288C showed state-dependent reaction with MTS only in the presence of agonist. M263C and S270C were also accessible to MTS labeling. Mutated residues more intracellular than M263C did not react, indicating a floor of the cavity. These data demonstrate that the conformational changes accompanying channel gating increase accessibility to amino acids critical for drug action in TM1, TM2, and TM3, which may provide a mechanism by which alcohols and anesthetics can act on glycine (and likely other) receptors
Bifenili idrossilati di origine naturale come leganti per recettori di tipo GABA<sub>A</sub>
L'unità bifenilica idrossilata è presente in un gran numero di composti naturali quali la
vancomicina, la bifenomicina e la classe della ellagitannine che conta in Natura più di 500
derivati. Il nostro gruppo di ricerca ha pubblicato recentemente la sintesi, la risoluzione e
l’attività biologica di nuove strutture bifeniliche idrossilate naturali-simili
Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon
Background and aims
Increased levels of chemokine interferon-gamma (IFN-γ)-inducible protein-10 (CXCL10),
soluble CD163 (sCD163) and soluble CD14 (sCD14) have been reported in HCV infection.
The aim of this study was to compare, sCD163 and sCD14 levels in HCV-infected patients
undergoing direct acting antiviral (DAA)-containing regimens with or without interferon
(IFN).
Methods
sCD163, sCD14 and CXCL10 were longitudinally measured by ELISA in 159 plasma samples from 25 HCV-infected patients undergoing IFN-based treatment plus telaprevir or
boceprevir and 28 HCV infected subjects treated with DAA IFN-free regimens. Twenty-five
healthy donors (HD) were included as controls.
Results
At baseline CXCL10, sCD163 and sCD14 levels were higher in HCV-infected patients than
in HD. CXCL10 and sCD163 levels were significantly decreased in responder (R) patients
who achieved sustained virological response (SVR), with both IFN-based and IFN-free regimens, while they were persistently elevated in non-responders (NR) patients who stopped
IFN-based treatments because of failure or adverse events. Conversely, sCD14 levels
were apparently unchanged during therapy, but at the end of treatment the levels reached
normal ranges. Comparing the two regimens, the extent of CXCL10 reduction was more
pronounced in patients undergoing DAA IFN-free therapies, whereas sCD163 and sCD14
reduction was similar in the two groups.
Interestingly, only in IFN-based regimens baseline sCD163 levels were significantly
higher in NR than in R patients, while in the IFN-free treatment group also patients with highsCD163 plasma levels obtained SVR. At the end of therapy, even if the biomarkers were
largely decreased, their levels remained significantly higher compared to HD. Only in the
early fibrosis stages, sCD163 values tended to normalize.
Conclusions
These results indicate that IFN-free regimens including newer DAA induce an early and
marked decrease in circulating inflammatory biomarkers. However, the full normalization of
biomarkers was not obtained, especially in patients with advanced fibrosis, thus underlying
the need for a treatment in the early stages of HCV infection
Nuovi derivati 1,2-difenil-imidazolici come potenti ed efficaci modulatori allosterici positivi del recettore GABA<sub>A</sub>
Il complesso recettoriale GABAA è il più importante recettore inibitorio presente nel
sistema nervoso centrale dei vertebrati. Il legame dell’acido γ-aminobutirrico (GABA) ai
recettori GABAA induce l’apertura di un intrinseco canale al Cl- con conseguente
iperpolarizzazione e inibizione della cellula. Recentemente presso i nostri laboratori abbiamo sviluppato una serie di 1,2-difenilimidazol-piperazine dotate di significativa affinità di legame per i recettori dopaminergici D2-
simili, serotoninergici 5-HT1A e 5-HT2A. La nostra attenzione si è focalizzata sulla capacità di
alcuni derivati di inibire in modo concentrazione-dipendente (0.1-300 µM) le correnti al Cl-
evocate dal GABA su recettori GABAA umani espressi in oociti di Xenopus
Liver fibrosis in HCV monoinfected and HIV/HCV coinfected patients: dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors TIMPs and effect of HCV protease inhibitors
An imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) may contribute to liver fibrosis in patients with hepatitis C (HCV) infection. We measured the circulating levels of different MMPs and TIMPs in HCV monoinfected and HIV/HCV coinfected patients and evaluated the potential for anti-HCV therapy to modulate MMP and TIMP levels in HCV subjects. We analyzed 83 plasma samples from 16 HCV monoinfected patients undergoing dual or triple anti-HCV therapy, 15 HIV/HCV coinfected patients with undetectable HIV load, and 10 healthy donors (HD). Levels of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10, TIMP-1, and TIMP-2 were measured by a SearchLight Multiplex Immunoassay Kit. MMP-2 and MMP-9 were the highest expressed MMPs among all the analyzed samples and their levels significantly increased in HCV monoinfected and HIV/HCV coinfected subjects compared to HD. TIMP-1 levels were significantly higher in HCV and HIV/HCV subjects compared to HD and were correlated with liver stiffness. These findings raise the possibility of using circulating TIMP-1 as a non-invasive marker of liver fibrosis in HCV infection. A longitudinal study demonstrated that MMP-9 levels significantly decreased (40% reduction from baseline) in patients receiving dual as well as triple direct-acting antivirals (DAA) anti-HCV therapy, which had no effect on MMP-2, TIMP-1, and TIMP-2. As the dysregulation of MMP-2 and MMP-9 may reflect inflammatory processes in the liver, the decrease of MMP-9 following HCV protease inhibitor treatment suggests a positive effect on the reduction of liver inflammation
Recommended from our members
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid
In the reward circuitry of the brain, alpha-7-nicotinic acetylcholine receptors (α7nAChRs) modulate effects of delta-9-tetrahydrocannabinol (THC), marijuana’s main psychoactive ingredient. Kynurenic acid (KYNA) is an endogenous negative allosteric modulator of α7nAChRs. Here we report that the kynurenine 3-monooxygenase (KMO) inhibitor Ro 61-8048 increases brain KYNA levels and attenuates cannabinoid-induced increases in extracellular dopamine in reward-related brain areas. In the self-administration model of drug abuse, Ro 61-8048 reduced the rewarding effects of THC and the synthetic cannabinoid WIN 55,212-2 in squirrel monkeys and rats, respectively, and it also prevented relapse to drug-seeking induced by re-exposure to cannabinoids or cannabinoid-associated cues. The effects of enhancing endogenous KYNA levels with Ro 61-8048 were prevented by positive allosteric modulators of α7nAChRs. Despite a clear need, there are currently no medications approved for treatment of marijuana dependence. Modulation of KYNA provides a novel pharmacological strategy for achieving abstinence from marijuana and preventing relapse
Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures
The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32–56) years were included. During the 1-year study period, sustained seizure freedom was achieved by 142 (14.3%) patients, of whom 72 (50.7%) were seizure-free from Day 1 of BRV treatment. Sustained seizure freedom was maintained for ≥6, ≥9, and 12 months by 14.3%, 11.9%, and 7.2% of patients from the study cohort. Sustained seizure response was reached by 383 (38.5%) patients; 236 of 383 (61.6%) achieved sustained ≥50% reduction in seizure frequency by Day 1, 94 of 383 (24.5%) by Month 4, and 53 of 383 (13.8%) by Month 7 up to Month 12. Adjunctive BRV was associated with sustained seizure frequency reduction from the first day of treatment in a subset of patients with uncontrolled focal epilepsy
- …